Deep brain stimulation (DBS) has been used for over 15 years to treat severe forms of Gilles de la Tourette syndrome (GTS) refractory to pharmacological and, more recently, cognitive-behavioral therapies (CBT) ( [@ref-10]). Despite the relatively small numbers of patients operated so far, the number of surgical targets is impressive ( [@ref-7]). The available double-blind trials favor the thalamus and the globus pallidus internus (both anteromedial and posteroventral parts) but the debate if these two are the best targets or if other targets need to be explored remains open ( [@ref-11]). As we have learnt from Parkinson disease, establishing just one or two consensual DBS targets is a long endeavour which requires time and a large number of patients ( [@ref-4]). Providing the latter will certainly be difficult in a comparatively rare disease like GTS.

Why so many potential targets in GTS? One of the main reasons appears to be the wish to diminish not only tics but also comorbidities (obsessive-compulsive disorder (OCD), impulsivity, attention deficit hyperactivity disorder (ADHD), anxiety, depression and others) which are present in almost 90% of patients meeting DSM criteria for GTS ( [@ref-1]). Specifically, these patients fall into the category named « full-blown GTS » by [@ref-8] and are also the most likely candidates to undergo surgery. Thus, a tailor-made, individualized approach might indeed make sense instead of including/randomizing patients into studies where a certain diagnostic uniformity is required or at least assumed.

I will argue that in an admittedly complex situation, Occam's razor is the way to go forward. First, there is no GTS without tics. Challenging DSM-5 criteria is understandable but unrealistic ( [@ref-9]). In clinical practice, however, even if DSM-5 criteria for GTS are met, we do of course establish the predominant symptoms in terms of impairment. Then, we chose the surgical target which we believe will be best suited to counter the main burden on the patient's quality of life. This may mean that a patient with severe tics but even more severe OCD might actually be operated predominantly for the latter, targeting the subthalamic nucleus, for instance, which is not a usual target in GTS ( [@ref-5]). However, if tics are the main problem, then these should be treated first and foremost, which does not prevent us from evaluating comorbidities pre- and post-op by appropriate scales, as is done anyway in most current trials ( [@ref-3]). But we should be clear, for the time being, that obtaining a direct, surgically-induced effect on comorbidities will be the cherry on the cake, not something that can be systematically expected, at least based on our current knowledge of basal ganglia circuitry. That, for instance, was the rationale of the Paris group to implant electrodes into the limbic portions of the GPi, hoping to also reduce behavioral manifestations of GTS ( [@ref-2]; [@ref-12]). In a similar vein, I am doubtful of implanting multiple electrodes in multiple sites in the hope of alleviating surgically a host of neuropsychiatric symptoms; although I admit that in rare, very debilitating cases, this might be an option to consider.

My take is rather this: having severe, relentless and debilitating tics tend to cloud comorbidities. In case of successful DBS, other symptoms, rather than being co-treated by electrode implantation, may actually re-emerge. However, the patient is now free to pursue other forms of treatment for these symptoms, for instance psychostimulants for the treatment of ADHD if these previously aggravated tics. Even more importantly, psychotherapeutic approaches thus far impossible, notably cognitive behavioural therapy (CBT), can become feasible. An example from the OCD world concerns patients who underwent a 24 week CBT treatment programme after DBS of the nucleus accumbens ( [@ref-6]). Not only did CBT offer further symptom improvement: rather, as the authors note, all patients (n=16) had undergone previous CBT trials (between 1 and 9) which were not only unsuccesful but sometimes counterproductive because they majored anxiety and fear. DBS appeared to alleviate these symptoms and thereby made successful CBT possible. In a similar vein, CBT aimed at further tic reduction could be tried post-op where, pre-op, it was unfeasible. The same applies for psychotherapeutical approaches aiming to improve OCD, depression, anxiety and behavioral problems.

Therefore, and in conclusion, I suggest to view DBS in GTS as a window or a stepping stone to a more holistic treatment rather than a single solution for all our patients' ailments.
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This is an interesting and thoughtful take on the approach to DBS in GTS. Because GTS is a complex neuropsychiatric syndrome with a variety of different symptoms (or comorbidities), it may not be reasonable to assume that all of these symptoms will be alleviated by DBS; to the contrary, they may actually appear to be worsening because they were previously being masked by the tics. As the author suggests, it is impossible to make accurate assessments of a treatment\'s effect without first appropriately classifying the phenomenology of the illness and/or symptoms being targeted.

This article shows familiarity with the literature and clear writing, and is entirely appropriate for an Opinion Article.

We add a few comments, hopefully to further the discussion. The author argues well for focusing clinical trials for DBS in GTS on one problem at a time, namely tics. However, as he notes, the great majority of patients with GTS have clinical features other than tics. [Gilbert and Buncher (2005)](https://www.ncbi.nlm.nih.gov/pubmed/16179653) ^[@rep-ref-16159-1]^ include this observation of multiple symptoms as one of several features that complicate performing and interpreting clinical trials in GTS. Focusing DBS on the most problematic symptom in each patient may even prove to produce better results than focusing DBS on tics. But we have insufficient data to make such a judgment. 

The issues identified by Prof. Hartmann highlight the critical importance of further clinical trials and of registering all DBS experience in GTS ^[@rep-ref-16159-2]^.

One trivial note: Substitute "exacerbated" for the word "majored" near the end of the article.

[Shan H. Siddiqi](http://f1000.com/prime/thefaculty/member/499999771097566010)

[Kevin J. Black](http://f1000.com/prime/thefaculty/member/499999771097516043)

We have read this submission. We believe that we have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.
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Professor Hartmann\'s opinion article is a clear-thinking and original critique of the directions that DBS for GTS is taking. The field is perhaps expanding faster than uncertainties are being addressed, partly due to the heterogenous nature of the condition and the possibility of several different surgical targets- variables that he surveys from an interesting perspective. I agree with him and Professor Cavanna that the practice of selecting modified surgical targets for tics based on comorbidites may lack a good evidence base, but the fundamental problem is establishing how to best to treat tics with DBS, including the prediction of beneficial effect for individual patients.The notion of DBS in GTS as an enabling therapy to allow conventional management strategies to be more successful needs further exploration and may prove an important principle.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.
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I found Andreas Hartmann's considerations on the use of Deep Brain Stimulation (DBS) for patients with Tourette syndrome (TS) both clinically sensible and thought-provoking. The article is clearly written and the take-home message is convincingly argued: patients with TS who are candidates to DBS present by definition with a clinical picture characterised by highly severe and refractory tics. Rather than considering DBS as a panacea for the multifaceted neurobehavioural spectrum complicating patients' presentations, the focus (and expectations) of DBS should remain anchored to tic alleviation. From a practical point of view, it has been observed that the DBS procedure can have wide-ranging effects, however the approach of *a priori* targeting multiple symptoms at the same time ("killing several birds with one stone") can be prone to theoretical and clinical fallacies. Conversely, it would be interesting to test the sequential approach proposed by the author by systematically assessing changes in health-related quality of life in patients undergoing tic-focused neuromodulation, followed by specific therapeutic interventions for the residual behavioural co-morbidities.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.
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